Withdrawal of anti-tumour necrosis factor α therapy in inflammatory bowel disease.

ABSTRACT: Anti-tumour necrosis factor α (anti-TNFα) therapy is an established treatment in inflammatory bowel disease. However, this treatment is associated with high costs and the possibility of severe adverse events representing a true challenge for patients, clinicians and health care systems. Consequently, a crucial question is raised namely if therapy can be stopped once remission is achieved and if so, how and in whom. Additionally, in a real-life clinical setting, discontinuation may also be considered for other reasons such as the patient's preference, pregnancy, social reasons as moving to countries or continents with less access, or different local policy or reimbursement. In contrast to initiation of anti-TNFα therapy guidelines regarding stopping of this treatment are missing. As a resul

SUBMITTER: Papamichael K 

PROVIDER: S-EPMC4408449 | biostudies-literature | 2015 Apr

REPOSITORIES: biostudies-literature